Maryland Joins Federal Sickle Cell Treatment Program

MARYLAND – The State of Maryland has recently joined the federal Cell and Gene Therapy (CGT) Access Model, allowing Medicaid participants in the state to more easily access cell and gene therapies for the disease. 

Participation in the CGT Access Model ensures better pricing in Maryland for high-cost medications. Under the model, the Centers for Medicare & Medicaid Services (CMS) negotiates supplemental, outcomes-based rebate agreements with pharmaceutical manufacturers for select participating Medicaid programs. This process helps to reduce costs and strengthen support services for patients and families who need access to these life-changing treatments.

“Maryland is committed to providing innovative and accessible health solutions designed specifically for our residents,” said Maryland Department of Health Secretary Dr. Meena Seshamani. “By signing on to the CGT Access Model, we are expanding the state’s ability to provide costly, life-saving treatments that will allow Medicaid participants access to the care they need.”

Approximately 3,000 Maryland Medicaid participants have sickle cell disease, though some may not meet the clinical criteria to qualify for either of the cell and gene therapies. The two sickle cell therapies currently available are already FDA-approved for those eligible. Participation in the model is estimated to save the State of Maryland more than $1 million per patient.